We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in Patients Undergoing LVAD Implantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01442129
Recruitment Status : Completed
First Posted : September 28, 2011
Results First Posted : October 13, 2014
Last Update Posted : May 1, 2015
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Deborah Ascheim, Icahn School of Medicine at Mount Sinai

Brief Summary:
The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe. MPCs are normally present in human bone marrow, and have been shown to increase the development of blood vessels and new heart muscle cells in the heart. In addition, this research is being done to test whether injecting the MPCs into the heart is effective in improving heart function.

Condition or disease Intervention/treatment Phase
Heart Failure Cardiomyopathy Ventricular Dysfunction Biological: MPC Intramyocardial injection Biological: Control Solution Phase 2

Detailed Description:
Intramyocardial injection of mesenchymal precursor cells (MPC) in patients with advanced heart failure who are treated with left ventricular assist device (LVAD) implantation may result in a renewable source of proliferating functional cardiomyocytes, as well as induce development of capillaries and larger size blood vessels to supply oxygen and nutrients to endogenous myocardium and newly-implanted cardiomyocytes, and release factors capable of paracrine signaling. If safety is established and an efficacy signal is observed in this exploratory trial, then the investigators will design a follow-up trial (stage 2) based on an adaptive design. The next trial would randomize patients to active therapy at one of two doses (25 and 75 million MPCs) versus placebo, and based on a predetermined selection criterion drop randomization to one of the dose arms as results accrue. Should this exploratory trial demonstrate safety but no signal of efficacy, then the subsequent trial would be based on a single dose of 75 million MPCs versus placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: LVAD Therapy: Exploring the Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function
Study Start Date : April 2012
Actual Primary Completion Date : March 2013
Actual Study Completion Date : August 2013

Arm Intervention/treatment
Experimental: MPC Intramyocardial injection
Intramyocardial injections of 25 million Mesenchymal Precursor Cells (MPCs)
Biological: MPC Intramyocardial injection
Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
Other Name: RevascorTM

Sham Comparator: Control Solution
Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
Biological: Control Solution
Injection of control solution during the LVAD implantation.
Other Name: Cryoprotective media

Primary Outcome Measures :
  1. Intervention Related Adverse Events [ Time Frame: 90 days ]
    The primary safety endpoint of this study is the incidence of the following potential study-intervention related adverse events within 90 days post intervention (LVAD implantation + intramyocardial injection of study product): infectious myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization.

Secondary Outcome Measures :
  1. Functional Status and Ventricular Function [ Time Frame: 90 days ]

    The key efficacy endpoint of this study is functional status and ventricular function, while weaned from LVAD support, at 90 days post intervention (LVAD implantation + intramyocardial injection of study product). Functional status is defined by the ability to tolerate wean from LVAD support for 30 minutes without signs or symptoms of hypoperfusion, including, but not limited to symptoms of low output or signs of vascular congestion. Ventricular function will be assessed by transthoracic echocardiogram (TTE) in those patients able to be weaned for 30 minutes from LVAD support.

    The number of participants who successfully tolerated the 30 minute wean from LVAD support at 90 days is reported.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent, inclusive of release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documentation;
  • Age 18 years or older;
  • If the subject or partner is of childbearing potential, he or she must be willing to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening and for a period of at least 16 weeks after procedure;
  • Female subjects of childbearing potential must have a negative serum pregnancy test at screening;
  • Admitted to the clinical center at the time of randomization;
  • Clinical indication and accepted candidate for implantation of an FDA approved implantable, non-pulsatile LVAD as a bridge to transplantation or for destination therapy.

Exclusion Criteria:

  • Planned percutaneous LVAD implantation;
  • Anticipated requirement for biventricular mechanical support;
  • Cardiothoracic surgery within 30 days prior to randomization;
  • Myocardial infarction within 30 days prior to randomization;
  • Prior cardiac transplantation, LV reduction surgery, or cardiomyoplasty;
  • Acute reversible cause of heart failure (e.g. myocarditis, profound hypothyroidism);
  • Stroke within 30 days prior to randomization;
  • Platelet count < 100,000/ul within 24 hours prior to randomization;
  • Active systemic infection within 48 hours prior to randomization;
  • Presence of >10% anti-human leukocyte antigen (anti-HLA) antibody titers with known specificity to the MPC donor HLA antigens;
  • A known hypersensitivity to dimethyl sulfoxide (DMSO), murine, and/or bovine products;
  • History of cancer prior to screening (excluding basal cell carcinoma);
  • Acute or chronic infectious disease, including but not limited to human immunodeficiency virus (HIV);
  • Received investigational intervention within 30 days prior to randomization;
  • Treatment and/or an incompleted follow-up treatment of any investigational cell based therapy within 6 months prior to randomization;
  • Active participation in other research therapy for cardiovascular repair/regeneration;
  • Prior recipient of stem precursor cell therapy for cardiac repair;
  • Pregnant or breastfeeding at time of randomization.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01442129

Layout table for location information
United States, Florida
University of Florida
Gainsville, Florida, United States, 32610
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Minnesota
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States, 55407
United States, New York
Montefiore Einstein Heart Center
Bronx, New York, United States, 10467
Columbia University Medical Center
New York, New York, United States, 10032
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Ohio State University
Columbus, Ohio, United States, 43210
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Baylor Research Institute
Dallas, Texas, United States, 75230
Texas Heart Institute
Houston, Texas, United States, 77030
Sponsors and Collaborators
Deborah Ascheim
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Study Chair: Timothy Gardner, MD Christiana Care Health Services
Study Chair: Patrick O'Gara, MD Brigham and Women's Hospital
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Deborah Ascheim, Associate Professor, Clinical Director of Research, InCHOIR, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT01442129    
Other Study ID Numbers: GCO 08-1078-00006
U01HL088942 ( U.S. NIH Grant/Contract )
U01HL088942-04 ( U.S. NIH Grant/Contract )
711 ( Other Identifier: Ct Surgery Network Research Group )
First Posted: September 28, 2011    Key Record Dates
Results First Posted: October 13, 2014
Last Update Posted: May 1, 2015
Last Verified: April 2015
Keywords provided by Deborah Ascheim, Icahn School of Medicine at Mount Sinai:
Heart Failure
Left Ventricular Assist Device
Heart Transplantation
Destination Therapy
Cell Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Ventricular Dysfunction
Heart Diseases
Cardiovascular Diseases